ValuEngine cut shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a hold rating to a sell rating in a report issued on Thursday.
A number of other research firms also recently weighed in on AMPH. BidaskClub upgraded shares of Amphastar Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, March 13th. BMO Capital Markets restated a market perform rating and issued a $19.00 price target (up from $17.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 13th. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, March 13th. Wells Fargo & Co restated a buy rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, March 21st. Finally, Needham & Company LLC restated a buy rating and issued a $24.00 price target (up from $23.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 13th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $21.33.
AMPH opened at $15.77 on Thursday. Amphastar Pharmaceuticals has a 1-year low of $14.40 and a 1-year high of $20.45. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.53 and a current ratio of 2.40. The company has a market capitalization of $735.10 million, a PE ratio of 68.57, a P/E/G ratio of 2.36 and a beta of 1.33.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Wednesday, May 9th. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.13). Amphastar Pharmaceuticals had a negative net margin of 1.50% and a positive return on equity of 3.39%. The company had revenue of $58.40 million during the quarter, compared to analyst estimates of $60.75 million. During the same quarter in the previous year, the business posted $0.09 earnings per share. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. analysts expect that Amphastar Pharmaceuticals will post 0.3 earnings per share for the current year.
In other news, CEO Jack Y. Zhang purchased 25,000 shares of the stock in a transaction on Tuesday, May 15th. The stock was purchased at an average price of $16.08 per share, for a total transaction of $402,000.00. Following the acquisition, the chief executive officer now owns 2,065,619 shares in the company, valued at $33,215,153.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Michael A. Zasloff sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 12th. The stock was sold at an average price of $16.52, for a total transaction of $247,800.00. Following the transaction, the director now owns 29,845 shares of the company’s stock, valued at approximately $493,039.40. The disclosure for this sale can be found here. 31.50% of the stock is owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP raised its holdings in Amphastar Pharmaceuticals by 3.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,685,448 shares of the company’s stock worth $31,602,000 after purchasing an additional 53,646 shares during the last quarter. Geode Capital Management LLC raised its holdings in Amphastar Pharmaceuticals by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 332,824 shares of the company’s stock worth $6,403,000 after purchasing an additional 5,435 shares during the last quarter. Millennium Management LLC raised its holdings in Amphastar Pharmaceuticals by 1,746.9% during the 4th quarter. Millennium Management LLC now owns 293,672 shares of the company’s stock worth $5,650,000 after purchasing an additional 277,771 shares during the last quarter. Principal Financial Group Inc. raised its holdings in Amphastar Pharmaceuticals by 2.2% during the 1st quarter. Principal Financial Group Inc. now owns 273,428 shares of the company’s stock worth $5,127,000 after purchasing an additional 5,789 shares during the last quarter. Finally, Cortina Asset Management LLC bought a new position in Amphastar Pharmaceuticals during the 1st quarter worth approximately $4,907,000. Hedge funds and other institutional investors own 44.12% of the company’s stock.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.